FDA awards orphan drug designation to Iecure's GTP-506 for OTC deficiency
Sep. 7, 2022
The FDA has granted orphan drug designation to Iecure Inc.'s lead product candidate GTP-506, an investigational product for the treatment of ornithine transcarbamylase (OTC) deficiency.
